Welcome to our dedicated page for Tourmaline Bio news (Ticker: $TRML), a resource for investors and traders seeking the latest updates and insights on Tourmaline Bio stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Tourmaline Bio's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Tourmaline Bio's position in the market.
Rhea-AI Summary
Tourmaline Bio, Inc. (TRML) announced key developments including the initiation of pivotal trials in Thyroid Eye Disease and Atherosclerotic Cardiovascular Disease, completion of a reverse merger and public offering, and financial results for 2023. The company expects cash runway until 2027 and aims to address unmet medical needs in immune and inflammatory diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.8%
Tags
-
Rhea-AI Summary
Tourmaline Bio, Inc. (TRML) CEO Sandeep Kulkarni to participate in investor conferences in March to discuss transformative medicines for immune and inflammatory diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.04%
Tags
-
News
Rhea-AI Summary
Tourmaline Bio, Inc. (TRML) announced that CEO Sandeep Kulkarni will present at the Guggenheim Healthcare Talks | 6th Annual Biotechnology Conference on February 7, 2024. The company is a late-stage clinical biotechnology firm focused on developing medicines for immune and inflammatory diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.46%
Tags
Rhea-AI Summary
Tourmaline Bio, Inc. announced the closing of its underwritten public offering of 5,307,691 shares of common stock, grossing approximately $172.5 million. The offering was made pursuant to a shelf registration statement on Form S-3 and was declared effective on August 25, 2022. The company now has 25,645,262 shares of common stock issued and outstanding as of January 29, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.26%
Tags
-
Rhea-AI Summary
Tourmaline Bio, Inc. announced the pricing of an underwritten public offering of 4,615,384 shares of its common stock at a public offering price of $32.50 per share, with expected gross proceeds of $150.0 million. The company has granted the underwriters a 30-day option to purchase up to an additional 692,307 shares of common stock at the public offering price. The offering is expected to close on January 29, 2024, subject to customary closing conditions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.33%
Tags
-
Rhea-AI Summary
Tourmaline Bio, Inc. (TRML) has announced a proposed underwritten public offering of its common stock. The company expects to grant the underwriters a 30-day option to purchase additional shares. The offering is made pursuant to a shelf registration statement filed with the SEC. Jefferies, Piper Sandler, Guggenheim Securities, and Truist Securities are acting as joint book-running managers for the offering.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.33%
Tags
Rhea-AI Summary
Tourmaline Bio, Inc. (TRML) plans to accelerate the initiation of a pivotal Phase 3 trial in 2024 for TOUR006 as first-line treatment for TED, with topline data expected in 2026. The company also reached alignment with the FDA on the clinical development program for ASCVD, including a Phase 2 trial evaluating quarterly dosing of TOUR006 in patients with cardiovascular risk. Tourmaline expects cash runway through 2026, including key TOUR006 data readouts in TED and cardiovascular disease.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.25%
Tags
-
Rhea-AI Summary
Tourmaline Bio, Inc. (TRML) has been added to the NASDAQ Biotechnology Index (NBI), effective prior to market open on December 18, 2023. The index is designed to track the performance of biotechnology and pharmaceutical securities listed on The Nasdaq Stock Market, calculated under a modified capitalization-weighted methodology. Companies must meet eligibility requirements, including minimum market capitalization, average daily trading volume, and seasoning as a public company, among other criteria. NASDAQ selects constituents once annually in December.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Tourmaline Bio, Inc. (NASDAQ: TRML) announced the appointment of Clay Siegall, PhD, as Chairman of the Board. Dr. Siegall, known for his successful leadership at Seagen, Inc., brings extensive experience in developing transformative medicines for patients with immune and inflammatory diseases. His appointment is expected to strengthen Tourmaline's ability to deliver innovative medicines and achieve important milestones.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.96%
Tags
Rhea-AI Summary
Tourmaline Bio, Inc. (Nasdaq: TRML) announced that CEO Sandeep Kulkarni will participate in investor conferences in November. The conferences include Guggenheim Healthcare 5th Annual I&I Conference, Truist Securities BioPharma Symposium, Jefferies London Healthcare Conference, and Piper Sandler 35th Annual Healthcare Conference. Live webcasts and replays will be available on the Tourmaline Bio website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.43%
Tags
Tourmaline Bio, Inc.
Nasdaq:TRML
TRML Rankings
TRML Stock Data
404.70M
16.00M
14.27%
56.41%
5.78%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
United States of America
NEW YORK
About TRML
talaris therapeutics is a late-clinical stage biotechnology company based in boston, ma and louisville, ky. talaris is developing transformative cell therapies with the potential to eliminate the burden of chronic immunosuppression for organ transplant recipients as well as induce durable remissions in patients with severe auto-immune and immune-mediated disorders. the company was founded on technology discovered and developed by dr. suzanne ildstad and operates its own cell processing facility in louisville. talaris is backed by leading life sciences investors blackstone life sciences, longitude capital and qiming venture partners usa.